Joint Rheumatology Program, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece.
Rheumatology Clinic, University of Ioannina, Ioannina, Greece.
Rheumatology (Oxford). 2021 May 14;60(5):2223-2230. doi: 10.1093/rheumatology/keaa557.
Predicting serious infections (SI) in patients with rheumatoid arthritis (RA) is crucial for the implementation of appropriate preventive measures. Here we aimed to identify risk factors for SI and to validate the RA Observation of Biologic Therapy (RABBIT) risk score in real-life settings.
A multi-centre, prospective, RA cohort study in Greece. Demographics, disease characteristics, treatments and comorbidities were documented at first evaluation and one year later. The incidence of SI was recorded and compared with the expected SI rate using the RABBIT risk score.
A total of 1557 RA patients were included. During follow-up, 38 SI were recorded [incidence rate ratio (IRR): 2.3/100 patient-years]. Patients who developed SI had longer disease duration, higher HAQ at first evaluation and were more likely to have a history of previous SI, chronic lung disease, cardiovascular disease and chronic kidney disease. By multivariate analysis, longer disease duration (IRR: 1.05; 95% CI: 1.005, 1.1), history of previous SI (IRR: 4.15; 95% CI: 1.7, 10.1), diabetes (IRR: 2.55; 95% CI: 1.06, 6.14), chronic lung disease (IRR: 3.14; 95% CI: 1.35, 7.27) and daily prednisolone dose ≥10 mg (IRR: 4.77; 95% CI: 1.47, 15.5) were independent risk factors for SI. Using the RABBIT risk score in 1359 patients, the expected SI incidence rate was 1.71/100 patient-years, not different from the observed (1.91/100 patient-years; P = 0.97).
In this large real-life, prospective study of RA patients, the incidence of SI was 2.3/100 patient-years. Longer disease duration, history of previous SI, comorbidities and high glucocorticoid dose were independently associated with SI. The RABBIT score accurately predicted SI in our cohort.
预测类风湿关节炎(RA)患者的严重感染(SI)对于实施适当的预防措施至关重要。本研究旨在确定 SI 的危险因素,并在真实环境中验证 RA 观察性生物治疗(RABBIT)风险评分。
这是一项在希腊进行的多中心、前瞻性 RA 队列研究。在首次评估和一年后记录患者的人口统计学、疾病特征、治疗方法和合并症。记录 SI 的发生率,并与 RABBIT 风险评分预测的 SI 发生率进行比较。
共纳入 1557 例 RA 患者。在随访期间,有 38 例患者发生 SI[发生率比(IRR):2.3/100 患者年]。发生 SI 的患者疾病病程更长,首次评估时的 HAQ 更高,且更有可能有既往 SI、慢性肺部疾病、心血管疾病和慢性肾脏病病史。多变量分析显示,疾病病程较长(IRR:1.05;95%CI:1.005,1.1)、有既往 SI 病史(IRR:4.15;95%CI:1.7,10.1)、糖尿病(IRR:2.55;95%CI:1.06,6.14)、慢性肺部疾病(IRR:3.14;95%CI:1.35,7.27)和每日泼尼松剂量≥10mg(IRR:4.77;95%CI:1.47,15.5)是 SI 的独立危险因素。在 1359 例患者中使用 RABBIT 风险评分,预计 SI 发生率为 1.71/100 患者年,与观察到的发生率(1.91/100 患者年;P=0.97)无差异。
在这项针对 RA 患者的大型真实前瞻性研究中,SI 的发生率为 2.3/100 患者年。病程较长、有既往 SI 病史、合并症和高糖皮质激素剂量与 SI 独立相关。RABBIT 评分准确预测了本队列的 SI。